Amarin

Alex Denner's firm takes over Amarin, ousts non-Sarissa board members
Alex Denner's firm takes over Amarin, ousts non-Sarissa board members
Endpoints
Amarin
Sarissa Capital
Alex Denner
Flag link:
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Yahoo/Benzinga
Amarin
Vascepa
Vazkepa
acute coronary syndrome
clinical trials
Flag link:
In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics
In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics
Fierce Pharma
Amarin
Hikma
legal
antitrust
generics
Vascepa
Flag link:
Struggling Amarin jousts with activist investor Sarissa as board vote nears
Struggling Amarin jousts with activist investor Sarissa as board vote nears
Fierce Pharma
Amarin
Vascepa
investors
Flag link:
Why Amarin Stock Tumbled This Week
Why Amarin Stock Tumbled This Week
Motley Fool
Amarin
Flag link:
Why Amarin Stock Was a Winner Today
Why Amarin Stock Was a Winner Today
Motley Fool
Amarin
Australia
Vazkepa
Vascepa
Flag link:
Amarin stands behind Vascepa after new analysis raises questions about its efficacy
Amarin stands behind Vascepa after new analysis raises questions about its efficacy
Fierce Pharma
Amarin
Vascepa
Flag link:
Amarin turns to job cuts as generics challenge its heart pill
Amarin turns to job cuts as generics challenge its heart pill
BioPharma Dive
Amarin
Vascepa
restructuring
layoffs
Flag link:
Amarin CFO resigns amid cost-cutting measures, staff reduction of 40%
Amarin CFO resigns amid cost-cutting measures, staff reduction of 40%
Endpoints
Amarin
restructuring
layoffs
Flag link:
Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe
Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe
Fierce Pharma
Amarin
earnings
Flag link:
With sales sagging, Amarin sees progress on new Vascepa digital effort in the US
With sales sagging, Amarin sees progress on new Vascepa digital effort in the US
Fierce Pharma
Amarin
Vascepa
digital marketing
digital pharma
Flag link:
End-of-Year Restructuring Means Layoffs for These Companies
End-of-Year Restructuring Means Layoffs for These Companies
BioSpace
restructuring
Rigel Pharmaceuticals
Zymergen
Esperion Therapeutics
Amarin
Theravance
Sanofi
Acorda Therapeutics
CureVac
Ziopharm Oncology
Flag link:
Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy
Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy
Fierce Pharma
Amarin
Vascepa
layoffs
generics
Flag link:
ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim
ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim
Fierce Pharma
Amarin
Vascepa
Hikma
Flag link:
Amarin's Vascepa patent defense ends in a loss at the Supreme Court
Amarin's Vascepa patent defense ends in a loss at the Supreme Court
Fierce Pharma
Amarin
Vascepa
Supreme Court
patents
Flag link:
Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets
Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets
BioSpace
Amarin
Pharma CEOs
John Thero
Vaskepa
Europe
Flag link:
Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic
Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic
Fierce Pharma
Amarin
Vascepa
Europe
Vazkepa
Flag link:
Amarin vs. the Generics: Who Will Win?
Amarin vs. the Generics: Who Will Win?
Motley Fool
Amarin
generics
Vascepa
patents
Flag link:
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
Fierce Pharma
Amarin
Vascepa
AHA
Flag link:
Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire
Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire
Endpoints
Amarin
Vascepa
patents
Flag link:

Pages